Institute for Quality and Efficiency in Health Care

Evolocumab: No hint of added benefit

Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia. ...

Dec 22, 2015
popularity0 comments 0